Compare OESX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OESX | CRBU |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 48.5M |
| IPO Year | 2007 | 2021 |
| Metric | OESX | CRBU |
|---|---|---|
| Price | $12.12 | $0.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $36.50 | $5.75 |
| AVG Volume (30 Days) | 33.0K | ★ 2.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $86,306,000.00 | N/A |
| Revenue This Year | $17.95 | $114.75 |
| Revenue Next Year | $10.38 | N/A |
| P/E Ratio | $50.11 | ★ N/A |
| Revenue Growth | ★ 8.26 | N/A |
| 52 Week Low | $8.58 | $0.40 |
| 52 Week High | $31.65 | $2.49 |
| Indicator | OESX | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 20.95 | 26.66 |
| Support Level | $8.98 | N/A |
| Resistance Level | $21.13 | $0.58 |
| Average True Range (ATR) | 1.51 | 0.04 |
| MACD | -0.79 | 0.02 |
| Stochastic Oscillator | 8.66 | 2.25 |
Orion Energy Systems Inc provide light emitting diode (LED) lighting systems, wireless Internet of Things (IoT) enabled control solutions, commercial and industrial electric vehicle charging infrastructure solutions and lighting and electrical maintenance services. It help its customers achieve their sustainability, energy savings and carbon footprint reduction goals through technology and exceptional service. It sell its products and services into many vertical markets within the broader commercial and industrial market segment. Primary verticals include box retail, manufacturing, warehousing/logistics, federal and municipal government, healthcare and schools. It has three segments Lighting, Maintenance, and EV segment. It generates majority of revenue from Lighting segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.